Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship

[1]  N. Sut,et al.  Sister chromatid exchanges in lymphocytes of nuclear medicine physicians. , 2003, Mutation research.

[2]  H. Thierens,et al.  Patient dosimetry for 131I-lipiodol therapy , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Michael Fenech,et al.  Biomarkers of genetic damage for cancer epidemiology. , 2002, Toxicology.

[4]  H. Thierens,et al.  Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  L. Migliore,et al.  Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131. , 2002, Mutation research.

[6]  E. Pauwels,et al.  Labeling of mixed leukocytes with (99m)Tc-HMPAO causes severe chromosomal aberrations in lymphocytes. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  M. Bilban,et al.  Genotoxic effects of radiotherapy and chemotherapy on circulating lymphocytes in patients with Hodgkin's disease. , 2001, Mutation research.

[8]  T. Zelentsova,et al.  About some physical mechanisms of statistics of radiation-induced effects formation and non-linear cell response in low dose area. , 2001, Radiation measurements.

[9]  K. Okazaki,et al.  Evaluation of the effect of 90Sr beta-radiation on human blood cells by chromosome aberration and single cell gel electrophoresis (comet assay) analysis. , 2001, Mutation research.

[10]  S. Mather,et al.  General aspects of the cellular response to low- and high-LET radiation , 2001, European Journal of Nuclear Medicine.

[11]  H. Koppeschaar,et al.  Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin , 2001, European Journal of Nuclear Medicine.

[12]  H. Thierens,et al.  Translocation frequencies measured in patients one year after radioactive iodine therapy for thyrotoxicosis , 2001, International journal of radiation biology.

[13]  E. Pauwels,et al.  Health effects of therapeutic use of 131I in hyperthyroidism. , 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[14]  Peltenburg Lt.  Radiosensitivity of tumor cells. Oncogenes and apoptosis. , 2000 .

[15]  C. Catena,et al.  Micronucleus yield and colorimetric test as indicators of damage in patients' lymphocytes after 131I therapy. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  R. Marcos,et al.  Equal induction and persistence of chromosome aberrations involving chromosomes 1, 4 and 10 in thyroid cancer patients treated with radioactive iodine. , 2000, Mutation research.

[17]  R. Marcos,et al.  Multicolour FISH detection of radioactive iodine-induced 17cen-p53 chromosomal breakage in buccal cells from therapeutically exposed patients. , 2000, Carcinogenesis.

[18]  J. Freitas.  Therapeutic options in the management of toxic and nontoxic nodular goiter. , 2000, Seminars in nuclear medicine.

[19]  R. Marcos,et al.  Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer , 1999, European Journal of Nuclear Medicine.

[20]  H. Thierens,et al.  Estimation of risk based on biological dosimetry for patients treated with radioiodine. , 1999, Nuclear medicine communications.

[21]  P. Venkatachalam,et al.  Estimation of dose in cancer patients treated with fractionated radiotherapy using translocation, dicentrics and micronuclei frequency in peripheral blood lymphocytes. , 1999, Mutation research.

[22]  R. Marcos,et al.  Low sensitivity of the sister chromatid exchange assay to detect the genotoxic effects of radioiodine therapy. , 1999, Mutagenesis.

[23]  C. Streffer,et al.  Micronuclei-biological indicator for retrospective dosimetry after exposure to ionizing radiation. , 1998, Mutation research.

[24]  M. Schlumberger,et al.  Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  N. Shuke,et al.  Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  A. Gepdiremen,et al.  Sister chromatid exchange analysis in patients exposed to low dose of iodine-131 for thyroid scintigraphy. , 1997, Mutation research.

[27]  T. Seyama,et al.  Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis , 1997, Oncogene.

[28]  H. Thierens,et al.  Flow cytometry as a quantitative and sensitive method to evaluate low dose radiation induced apoptosis in vitro in human peripheral blood lymphocytes. , 1997, International journal of radiation biology.

[29]  M. Schlumberger,et al.  Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  C. Streffer,et al.  Micronuclei: a biological indicator of radiation damage. , 1996, Mutation research.

[31]  M. Dottorini.  Genetic risk assessment after iodine-131 exposure: an opportunity and obligation for nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  A. Pinchera,et al.  Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  B. Dubray,et al.  In vivo induction of apoptosis in human lymphocytes by therapeutic fractionated total body irradiation. , 1995, The British journal of radiology.

[34]  J. Little.  Cellular, molecular, and carcinogenic effects of radiation. , 1993, Hematology/oncology clinics of North America.

[35]  O. Monteiro Gil,et al.  Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. , 2000, Mutagenesis.

[36]  H. Thierens,et al.  Adaptive response in patients treated with 131I. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  M. Spitz,et al.  Chromosome breaks and sister chromatid exchange as predictors of second cancers in Hodgkin's disease. , 1998, Leukemia & lymphoma.

[38]  R. Marcos,et al.  Application of the single cell gel electrophoresis (SCGE) assay to the detection of DNA damage induced by 131I treatment in hyperthyroidism patients. , 1998, Mutagenesis.

[39]  C. Streffer,et al.  Micronuclei in lymphocytes of children from the vicinity of Chernobyl before and after 131I therapy for thyroid cancer. , 1996, International journal of radiation biology.

[40]  H. Elson,et al.  Effect of in vivo exposure to iodine-131 on the frequency and persistence of micronuclei in human lymphocytes. , 1993, Journal of toxicology and environmental health.